Map claims to evidence strength, expert review status, uncertainty, and revision history. Confidence states: preliminary → evidence-backed → expert-reviewed → revised.
| Claim | Evidence | Expert status | Uncertainty | Confidence | Sources | Share |
|---|---|---|---|---|---|---|
| Potency assay ambiguity remains one of the central bottlenecks in therapeutic EV development. Without a mechanism-linked potency assay, batch release and comparability are weakened. | High | pending | Medium | evidence backed | ||
| Local and topical EV applications may be more practical than broad systemic regenerative EV therapy. Delivery route and exposure drive CMC burden and clinical feasibility. | Medium | pending | Low-medium | evidence backed | ||
| Engineered EV delivery platforms must demonstrate clear advantage over LNP, AAV, and other established delivery modalities. Capital and development timelines require differentiated delivery economics and biodistribution. | High | pending | Medium | preliminary | ||
| Unapproved exosome clinic products carry significant regulatory and patient-safety risk and are not a credible venture pathway. Therapeutic claims require IND-enabled GMP development, not cash-pay clinic economics. | High | documented | Low | evidence backed | ||
| EV manufacturing is improving but remains a CMC-heavy, non-commodity process—not plug-and-play biologics manufacturing. COGS, facility design, and comparability drive venture capital intensity and timeline risk. | High | pending | Medium | evidence backed | ||
| Isolation and purification method largely defines the therapeutic EV product identity. Process changes without comparability data are regulatory and investment red flags. | High | pending | Low | evidence backed |
Unapproved exosome clinic products carry significant regulatory and patient-safety risk and are not a credible venture pathway.
Therapeutic claims require IND-enabled GMP development, not cash-pay clinic economics.
U.S. FDA (2019). Public Safety Notification on Exosome Products
No FDA-approved exosome products; exosomes for disease treatment are regulated as drugs/biologics requiring premarket approval.
Open source →Supports claims: exosome_clinic_regulatory_risk
U.S. FDA (2020). Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes
FDA authority over exosome products; warns against illegally marketed products with unsubstantiated claims.
Open source →Supports claims: exosome_clinic_regulatory_risk
U.S. FDA (2019). Public Safety Alert: Marketing of Unapproved Stem Cell and Exosome Products
Serious adverse events linked to unapproved exosome products; clinics may misrepresent regulatory status.
Open source →Supports claims: exosome_clinic_regulatory_risk
U.S. CDC (2019). Stem Cell and Exosome Products (CDC HAI)
CDC collaboration with FDA on serious adverse events from unapproved exosome products in Nebraska.
Open source →Supports claims: exosome_clinic_regulatory_risk
Example only: reviewers often flag potency assays that measure generic immunomodulation without linkage to intended MOA in the target indication.
No revisions yet. Revisions will appear after expert feedback updates claim text.